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Abstract
Background: Tuberculosis causes 3 million deaths annually. The most common site of tuberculosis is
pulmonary however; extra-pulmonary forms of the disease also remain prevalent. Restriction of
Mycobacterium tuberculosis depends on effective recruitment and subsequent activation of T lymphocytes,
mononuclear and polymorphonuclear cells to the site of infection. Tumor necrosis factor (TNF)-α is
essential for granuloma formation and is a potent activator of monocyte chemotactic protein (MCP-1,
CCL2). CCL2 is essential for recruitment of monocytes and T cells and has been shown to play a role in
protection against tuberculosis. Interleukin -8 (CXCL8) is a potent activator of neutrophils. Increased
levels of CCL2, CXCL8 and TNFα are reported in tuberculosis but their significance in different forms of
tuberculosis is as yet unclear. We have used an ex vivo assay to investigate differences in immune
parameters in patients with either pulmonary or extra-pulmonary tuberculosis.
Methods: Serum levels of CCL2, CXCL8 and TNFα were measured in patients with pulmonary
tuberculosis (N = 12), extra-pulmonary tuberculosis (N = 8) and BCG-vaccinated healthy volunteers (N
= 12). Whole blood cells were stimulated with non-pathogenic Mycobacterium bovis bacille-Calmette
Guerin (BCG) vaccine strain or bacterial lipopolysaccharide (LPS) and cyto/chemokines were monitored
in supernatants.
Results: Circulating serum levels of CXCL8 and TNFα were raised in all tuberculosis patients, while
CCL2 levels were not. There was no difference in spontaneous cytokine secretion from whole blood cells
between patients and controls. M. bovis BCG-induced ex vivo CCL2 secretion was significantly greater in
pulmonary as compared with both extra-pulmonary tuberculosis patients and endemic controls. In
response to LPS stimulation, patients with pulmonary tuberculosis showed increased CCL2 and TNFα
responses as compared with the extra-pulmonary group. BCG-, and LPS-induced CXCL8 secretion was
comparable between patients and controls.
Conclusion: CCL2 is activated by TNFα and is essential for recruitment of monocytes and T cells to the
site of mycobacterial infection. Increased CCL2 activation in pulmonary tuberculosis may result in a
stronger cellular response as compared with extra-pulmonary tuberculosis patients, and this may
contribute to the localization of infection to the pulmonary site.
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Background
Tuberculosis is a major cause of morbidity and mortality
worldwide, causing approximately 3 millions deaths
annually [1]. Mycobacterium tuberculosis, the causative
agent of tuberculosis is a successful pathogen due to its
ability to down regulate host immune responses. The pri-
mary site of infection for M. tuberculosis is the alveolar
macrophage. In cases where pulmonary infection cannot
be controlled the organism disseminates via blood to
other sites. Pulmonary involvement is seen in the majority
of tuberculosis cases however infections of extra-pulmo-
nary sites such as lymph nodes, skeletal, abdominal and
genito-urinary sites also remain common [2].
Local cellular responses required for restriction of infec-
tion with M. tuberculosis are fairly well understood. Gran-
ulomas which are the characteristic histopathologic
lesions of tuberculosis can be formed in any infected tis-
sue. Granulomas exhibit a characteristic mixture of mac-
rophages and lymphocytes and the outcome of infection
depends on the interplay between immune activating
cytokines produced at this site. T cell interferon -gamma
(IFN-γ) and macrophage activating tumor necrosis factor-
alpha (TNFα) are critical for protection and play a central
role in granuloma formation [3,4]. Recent studies have
also indicated an important role for chemokines in gran-
uloma formation [5,6].
Chemokines are small mass chemotactic cytokines pro-
duced by epithelial cells, mast cells, monocytes and neu-
trophils. Chemokines can be grouped into structurally
different families including C-C chemokines; monocyte
chemotactic protein-1 (MCP-1, CCL2), macrophage
inflammatory protein-1α (MIP-1α, CCL3), MIP-1β
(CCL4) and regulated-upon-activation, normally T-cell-
expressed and-secreted (RANTES, CCL5) and C-X-C
chemokines such as, IL-8 (CXCL8), MIG (CXCL9) and IP-
10 (CXCL10). These are all activated by M. tuberculosis [7].
CCL2 is the most potent chemoattractant and activator for
monocytes and attracts CD4 and γδ T cells [8]. CCL2 has
also been shown to play a role in protection against
murine tuberculosis [9-11]. CXCL8 is the most potent
attractant and activating factor for neutrophils and is
chemotactic for lymphocytes [12,13]. CXCL8 is required
for stimulation of a pro-inflammatory response against
M. tuberculosis and its components [14].
Previous studies have shown that in vivo (circulating)
serum levels of IFNγ, IL-10 [15], TNFα [16], CXCL8 and
IL-6 [17] are raised in pulmonary tuberculosis. Circulating
levels of chemokines CXCL8, CCL2 and RANTES are
raised in bronchoalveolar lavage fluid (BALF) and alveo-
lar macrophages from pulmonary tuberculosis patients
[18,19]. Increased CXCL8 and CCL2 activation is also
observed in patients with tuberculous pleurisy [20] and
meningitis [21,22]. In addition, the expression levels of
cytokines and chemokines have been correlated with dis-
ease severity [15] and with subsequent recovery after treat-
ment [23,24].
We have focused on immune responses in newly diag-
nosed untreated tuberculosis patients with either pulmo-
nary, or extra-pulmonary disease. We observed that
systemic levels of CXCL8 and TNFα were raised in all
patients while CCL2 was not. Using an ex vivo whole
blood assay we observed differential Mycobacterium-
induced and LPS stimulated responses between patients
with pulmonary and extra-pulmonary tuberculosis. Myco-
bacterium-induced CCL2 and TNFα, and LPS-induced
TNFα responses were greater in pulmonary as compared
with extra-pulmonary tuberculosis. However, both Myco-
bacterium-, and LPS-induced CXCL8 responses were com-
parable between patient groups.
Results
Patient characteristics
Hematological characteristics of tuberculosis patients and
healthy endemic controls are shown in Table 1. Median
values obtained for pulmonary (Pul-TB) and extra-pulmo-
nary tuberculosis (EPul-TB) were not different from con-
trols, although for total lymphocyte and neutrophil
counts were higher in tuberculosis patients. The erythro-
cyte sedimentation rate was raised in both patient groups
as compared with controls.
Serum CCL2, CXCL8 and TNFα in tuberculosis patients
We determined circulating levels of CCL2, CXCL8 and
TNFα in sera of pulmonary and extra-pulmonary tubercu-
losis patients and controls (Figure 1). No difference was
observed in serum CCL2 levels between the Pul-TB, EPul-
TB and control (EC) groups (Fig. 1A). However, serum
CXCL8 was significantly greater in both Pul-TB (P =
0.003) and EPul-TB (P = 0.002) as compared with con-
trols (Fig. 1B). Serum TNFα was also significantly greater
in both Pul-TB (P = 0.001) and in EPul-TB (P = 0.001) as
compared with controls (Fig. 1C).
BCG-, and LPS -induced CCL2, CXCL8 and TNFα
A time course profile of M. bovis BCG – and LPS-induced
CCL2, CXCL8 and TNFα secretion was determined in
healthy controls, see Fig. 2. BCG infection induced CXCL8
secretion within 6 – 18 h post stimulation (Fig. 2B), fol-
lowed by TNFα (Fig. 2C) and then by CCL2 (Fig. 2A). LPS
induced higher levels of all three cytokines as compared
with BCG. In addition, CXCL8, TNF α and CCL2 were
secreted more rapidly by LPS. Peak secretion of chemo/
cytokines was observed between 18 and 48 h post-stimu-
lation, therefore BCG and LPS induced responses were
subsequently studied at these time intervals.
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CCL2, CXCL8 and TNFα secretion in whole blood cells 
from tuberculosis patients
Baseline (spontaneous) levels of CCL2, CXCL8 and TNFα
were determined in Pul-TB, EPul-TB and control groups.
Chemokine activity was measured in supernatants of un-
stimulated whole blood cells after 18 h and 48 h of ex vivo
culture. At 18 h, increased levels of CCL2 were observed in
the Pul-TB group; 438 pg/ml (median) (range, 0–3000
pg/ml) as compared with EPul-TB; 35 pg/ml (0–774 pg/
ml) and controls; 42 pg/ml (0–102 pg/ml). Spontaneous
secretion of CXCL8 after 18 h was : Pul-TB; 284 pg/ml
(15–1927 pg/ml), EPul-TB; 681 pg/ml (1–2076 pg/ml)
and controls; 121 pg/ml (8–2546 pg/ml). Spontaneous
TNFα secretion at 18 h was: Pul-TB; 5 pg/ml (0–55 pg/
ml), E-Pul-TB; 1 pg/ml (0–585 pg/ml) and controls; 25
pg/ml (0–102 pg/ml). There were no significant differ-
ences between groups in their baseline levels of CCL2,
CXCL8 or TNFα (P > 0.05). Spontaneous levels of
cytokines measured after 48 h (data not shown) of in vitro
culture showed a similar trend as observed at 18 h, with
no difference between groups.
We subsequently investigated LPS-induced CCL2, CXCL8
and TNFα in tuberculosis patients. Table 2 illustrates
chemokine activity measured at 18 and 48 h post LPS
stimulation. Spontaneous chemokine secretion (indi-
cated above) have been subtracted from the values indi-
cated in the table. LPS-induced CCL2 activation in Pul-TB
was significantly greater than in EPul-TB at 18 h (*1, P =
0.01) and at 48 h (*2, P = 0.02) post-stimulation. LPS-
induced CXCL8 secretion was comparable between
patients and endemic controls. At 18 h, TNFα was signifi-
cantly greater in Pul-TB as compared with EPul-TB (*4, P
= 0.003) and also as compared with controls (*3, P =
0.003), whilst no difference was observed between these
groups at 48 h.
BCG-induced chemokine secretion in tuberculosis
patients and controls at 18 h post-stimulation is illus-
trated in Fig. 3. Baseline levels of chemokine secretion
have been subtracted and are described in the text above.
BCG- induced CCL2 was significantly greater in
pulmonary tuberculosis as compared with extra-pulmo-
nary at both 18 h (P = 0.001) (Fig. 3A) and 48 h (P = 0.02,
data not shown) post-stimulation. CCL2 secreted in
Table 1: Hematological characteristics of study subjects
Group Pul-TB, N = 10 Median (range) EPul-TB, N = 8 Median (range) Controls, N = 12 Median (range)
Age (y) 25 (15 – 50) 32 (15 – 58) 26 (18–29)
TLC (10 xE9/L) 9.8 (7 – 22.2) 9.4 (6.4 – 16.3) 7.2 (3 – 9)
Neutrophils (%) 64 (38 – 87) 70 (60 – 90 56 (38.1 – 70.6)
Monocytes (%) 6.7 (3.6 – 9.2) 7.4 (1.7 – 11.4) 7.2 (5.8 – 9.4)
ESR (mm/h) 60* (40–100) 50* (20–80) 0–3
M. tuberculosis+a 9/10 3 / 8 NA
%PPD+ (No. tested) 80 (8) 50 (4) 50 (12)
a Sputum/Biopsy/Culture positive for M. tuberculosis. Pulmonary tuberculosis (Pul-TB), extra-pulmonary tuberculosis (EPul-TB), purified protein 
derivative (PPD) skin test, total lymphocyte count (TLC), erythrocyte sedimentation rate (ESR), NA -not applicable. '*' P < 0.05 as compared with 
Controls.
Table 2: LPS-induced CCL2, CXCL8 and TNFα secretion in TB patients
Chemo/cytokines pg/ml Median (range)
Group Time (h) ∆CCL2 ∆CXCL8 ∆TNFα
EC (N = 12) 18 754 (17–3058) 1712 (788–2786) *3 1153 (0–1489)
48 1881 (713–7164) 1996 (1823–2977) 625 (211–858)
Pul (N = 10) 18 *1 1218 (765–2254) 1175 (318–2770) *3,4 2154 (1244–4852)
48 *2 3398 (1643–7012) 1190 (0–3249) 957 (74–1869)
E-Pul (N = 8) 18 *1 33 (0–818) 727 (0–1219) *4 577 (0–2180)
48 *2 32 (0–1194) 915 (0–1574) 73 (0–1821)
All values are '∆' after baseline subtraction of CCL2, CXCL8 or TNFα from each group. Pair-wise analysis was carried out to determine differences 
between groups using Mann-Whitney – U test '*' P ≤ 0.05. '1–4' defines pairs of values that were statistically significant from each other; Endemic 
controls (EC), Pul-TB (pulmonary tuberculosis), EPul-TB (extra-pulmonary tuberculosis).
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Raised CXCL8 and TNFα in sera of tuberculosis patientsFigure 1
Raised CXCL8 and TNFα in sera of tuberculosis patients. Circulating levels of chemo/cytokines were determined in 
sera of endemic controls (EC, N = 12), pulmonary tuberculosis (Pul-TB, N = 10) and extra-pulmonary tuberculosis (EPul-TB, N 
= 8) patients. Values for individual subjects are shown, with the median value indicated by a horizontal line. A. CCL2, B. 
CXCL8 and C. TNFα. Statistical analysis was carried out using the Mann Whitney-U test with significant differences, P < 0.05, 
'*'.
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Time-dependent secretion of Mycobacterium-, and LPS- induced CCL2, CXCL8 and TNFαF gure 2
Time-dependent secretion of Mycobacterium-, and LPS- induced CCL2, CXCL8 and TNFα. Whole blood cells 
(106) from healthy controls (N = 12) were stimulated with M. bovis BCG (2 × 105 CFU/ml, ratio of 0.2 bacilli per cell) and LPS 
at 0.1 µg/ml. Supernatants were harvested at 1, 6, 18, 48 and 120 h post-stimulation and tested for cytokine activity. Mean val-
ues are illustrated with SD indicated as 'y' error bars. A. CCL2, B. CXCL8, C. TNFα. Un-stimulated cells (spon) '?', BCG stim-
ulated '■' and LPS stimulated '▲'.
1
10
100
1000
10000
1 6 18 48 120
Time (h)
T
N
F
αα αα
(p
g
/m
l)
spon
BCG
LPS
A.
B.
C.
1
10
100
1000
10000
1 6 18 48 120
Time (h)
C
C
L
2
(p
g
/m
l) spon
BCG
LPS
1
10
100
1000
10000
1 6 18 48 120
Time (h)
C
X
C
L
8
(p
g
/m
l) spon
BCG
LPS
BMC Immunology 2005, 6:14 http://www.biomedcentral.com/1471-2172/6/14
Page 6 of 10
(page number not for citation purposes)
whole blood cells from pulmonary patients was also
greater as compared with controls at 18 h (P = 0.05) (Fig.
3A) and 48 h (P < 0.001, data not shown). There was no
difference in BCG-induced CXCL8 between pulmonary or
extra-pulmonary tuberculosis patients. Similarly, no dif-
ference was noted between patients and controls at both
time points studied (18 h, Fig. 3B; 48 h, data not shown).
In addition, we did not observe any differences in BCG-
induced TNFα between controls and tuberculosis
patients, P > 0.05 (Fig. 3C) at either time interval studied.
Although the trend of TNFα secretion was lower in the
extra-pulmonary group as compared with the pulmonary
group, this difference was also not significant.
Discussion
We have used an ex vivo whole blood assay to study differ-
ences in immune parameters in pulmonary and extra-pul-
monary tuberculosis. We observed that BCG-induced
CCL2 responses in pulmonary tuberculosis were greater as
compared to both extra-pulmonary tuberculosis and con-
trol groups. LPS stimulated CCL2 and TNFα responses
were also raised in pulmonary tuberculosis as compared
with extra-pulmonary tuberculosis patients.
We included both PPD skin test positive and negative
individuals to be representative of our healthy endemic
population, where a large proportion of BCG vaccinated
individuals remain non-reactive to the PPD skin test anti-
gen [25]. Our tuberculosis patient group was small
because of stringent selection criteria. We excluded most
of those patients who had received some form of anti-
tuberculous treatment for any length of time. Due to poor
therapeutic practices in Pakistan the majority of patients
presenting to a tertiary care center such as AKUH have
received variable course anti-tuberculous therapy [26].
There were three times as many female than male patients
in our study and this ratio is representative of female pre-
ponderance in the disease pattern in Pakistan [27]. In con-
gruence with previous studies, neutrophils and monocyte
counts were not significantly altered in patient groups
[28]. However, erythrocyte sedimentation was signifi-
cantly higher in tuberculosis patients, reflective of active
infection [28]. Two extra-pulmonary tuberculosis patients
(abdominal and lymphnode respectively) showed lung
involvement on chest X-ray. These were grouped based on
their predominant extra-pulmonary disease site and
found that their responses correlated with others in the
group.
The raised circulating levels of CXCL8 we observe in tuber-
culosis patients correlate with previous reports [16,17].
Increased CXCL8 has been associated with increased neu-
trophils in broncho-alveolar lavage [18] and pleural fluid
[29]. However, we did not find increased neutrophils or
monocytes in peripheral circulation of our patients. We
observed raised TNFα in sera of tuberculosis patients. This
is contrast to reports by Juffermans et al. who found that
TNFα was not raised in sera of tuberculosis patients [30],
while additional reports by Olobo et al. indicate that
serum TNFα is increased in healthy contacts [31]. We did
not observe any increase in circulating CCL2, correlating
with reports by Lee et al. [32] who compared sera from
tuberculosis patients with healthy tuberculin reactive con-
trols from a disease endemic region. This was in contrast
with Juffermans et al. who observed raised CCL2 in sera of
tuberculosis patients as compared with healthy individu-
als from a non-endemic region [16].
Ex vivo stimulation of whole blood leucocytes provides
useful information on control of cytokine secretion, since
it utilizes the host environment [33]. Whole blood assays
have been shown to provide useful insight into the immu-
nopathology of tuberculosis infection [34]. The time
course profiles of CCL2, CXCL8 and TNFα secretion we
observed in response to BCG and LPS corresponded to
previous reports of Mycobacterium and LPS induced activa-
tion of purified monocytes and adherent cells [19,35,36].
Further, after LPS stimulation we observed greater
cytokine activation than after mycobacterial stimulation
as has been shown in the case of cytokines such as CXCL8
[37]. Therefore the data we obtained using our whole
blood assay correlated with patterns observed using puri-
fied subsets of cells.
Increased CCL2 in pulmonary tuberculosis may be related
to localization of infection to the lung and may subse-
quently prevent disease dissemination. We observed
raised CCL2 in pulmonary tuberculosis compared with
controls in response to BCG stimulation. Raised CCL2
activation in tuberculosis correlates with previous studies
[19,32,38]. However, this contrasts with reports by Lee et
al. who did not observe any increase in CCL2 secreted by
adherent cells from pulmonary tuberculosis patients as
compared with healthy tuberculin reactors – in response
to PPD or M. tuberculosis 30 kD antigen [32]. One differ-
ence as compared to our study was that Lee et al. used
healthy controls with a PPD skin test induration > 15 mm,
while our control group comprised of either PPD negative
or PPD positive individuals with induration > 10 mm. In
addition, the use of live Mycobacteria and unprocessed
whole blood is likely to give more physiologically relevant
results for in vivo chemokine and cytokine activation as
compared with recombinant antigen or subunit prepara-
tions. We also observed greater CCL2 activation in pulmo-
nary tuberculosis as compared with extra-pulmonary
disease in response to both BCG and LPS stimulation.
LPS-induced CXCL8 was not raised in whole blood cells
from patients and this was paradoxical with increased lev-
els in sera of these patients. Differences between in vivo
BMC Immunology 2005, 6:14 http://www.biomedcentral.com/1471-2172/6/14
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Increased BCG-induced CCL2 secretion in pulmonary tuberculosisFigure 3
Increased BCG-induced CCL2 secretion in pulmonary tuberculosis. Whole blood cells were stimulated with M. bovis 
BCG as described in Fig. 2 and chemo/cytokine secretion measured at 18 h post-stimulation. Data for individual subjects; con-
trols 'EC' (N = 12), pulmonary 'Pul-TB' (N = 10) and extra pulmonary 'EPul-TB' (N = 8) tuberculosis is illustrated. The median 
value is indicated by a horizontal line. Baseline levels of cytokines have been subtracted in each case '∆ '. A. CCL2, B. CXCL8 
and C. TNFα. Pair-wise differences were calculated using the Mann-Whitney U test with P < 0.05, '*'.
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(serum and plasma) and in vitro (PBMC-induced
cytokine) activation have been shown previously [39].
Previously, we have shown increased spontaneous CXCL8
in disseminated mycobacterial (leprosy) infections while
inducible CXCL8 was not raised in patients [40]. There-
fore, increased levels of CXCL8 in sera may be indicative
of pathology in these patients and may not contribute to
the effective recruitment of cells.
TNFα levels were raised in pulmonary as compared with
both extra-pulmonary tuberculosis and controls in
response to LPS but not BCG stimulation. This difference
in TNFα levels was evident at the earlier (18 h) but not
later time interval. Probably, due to the reduced time
course profile of TNFα by 48 h. Lack of difference in TNFα
in response to BCG between groups, may also be due to
reduced overall levels induced by mycobacterium as com-
pared with the LPS.
Conclusion
Macrophages and other polymorphonuclear cells play
essential roles in initiation and maintenance of immune
responses to M. tuberculosis. Pro-inflammatory TNFα,
CCL2 and CXCL8 are important in maintaining a balance
between recruitment of other macrophages and also T
cells to restrict infection. CCL2 contributes to anti-myco-
bacterial inflammatory response by attracting monocytes
and T lymphocytes. Raised CCL2 in pulmonary tuberculo-
sis may lead to greater monocyte mediated immunity.
Reduced CCL2 concomitant with lowered TNFα in extra-
pulmonary tuberculosis may lead to lowered protective
cellular responses and increased dissemination in these
patients.
Methods
Subject selection and diagnosis
Patients were recruited from the Aga Khan University
(AKUH) and Masoomeen Hospitals in Karachi. Ethical
Clearance was obtained from the AKUH Human Subjects
Protection and Ethical Review Committee and samples
were taken from patients with informed consent. All study
subjects were examined and investigated by infectious dis-
eases consultants. Patients with significant co-morbid
conditions including diabetes mellitus, chronic renal fail-
ure, chronic liver disease, those on high dose corticoster-
oid therapy and those with HIV/AIDS were excluded from
this analysis. All patients were untreated except for two
who had been on anti-tuberculous therapy for 2 months
each due to delays in diagnostic confirmation of extra-
pulmonary tuberculosis. Patients were diagnosed by clin-
ical examination, chest X-ray, sputum M. tuberculosis
microscopy and culture. Chest X-rays were evaluated by
one of the consulting physicians using the classification of
the National Tuberculosis Association of the USA into
minimal, moderate and advanced lung tissue involve-
ment [41]. Microscopy was performed using Ziehl-
Neelsen staining. Cultures were done by means of a set of
Lowenstein Jensen slants with and without glycerol. Puri-
fied protein derivative (PPD) skin test was carried out on
each study subject. PPD skin test negative were those with
induration < 10 mm, with PPD positive with induration =
10 mm. Hematological parameters for all subjects were
noted on the date of enrollment and shown in Table 1.
The pulmonary tuberculosis (Pul-TB) group comprised of
10 patients (3 males and 7 females) with moderate dis-
ease and no other site involved except the lung. The extra-
pulmonary tuberculosis (EPul-TB) group comprised of 8
patients (2 males and 6 females) with tuberculosis in the
following sites; lymph nodes (N = 3), pericardial effusion
(N = 2), meningitis (N = 1), abdomen (N = 2). Of the
EPul-TB patients, 6/8 were confirmed on M. tuberculosis
smear/culture and/or radiology, while 2/8 were diagnosed
on the basis of clinical presentation and a favorable
response to anti-tuberculosis drugs. Two of the EPul-TB
patients also showed pulmonary involvement on Chest X-
ray. Twelve BCG-vaccinated healthy endemic controls
(EC) (9 males and 3 females) who were staff at the AKUH
were also included in the study. PPD+ volunteers had nor-
mal chest X-Ray and no clinical evidence of active disease.
Mycobacterium culture
Mycobacterium bovis BCG (Montreal vaccine strain) was
grown to logarithmic phase in 7H9 Middlebrook medium
with supplements (DIFCO Laboratories, MI, USA).
Mycobacteria were frozen in growth medium containing
20 % glycerol and stored at -70°C in single use aliquots
for the assay as described previously [40]. Mycobacterial
viability was confirmed prior to assays by fluorescent
staining [42] and by colony counts on Middlebrook 7H11
agar.
Whole blood assays
Venous blood was diluted 1: 10 in RPMI-1640 medium
each well containing 106 whole blood cells was set up as
per protocol [34]. Freshly thawed aliquots of BCG were
washed in PBS and diluted to infect cells as described pre-
viously [43]. Each was stimulated with either E. coli
lipopolysaccharide (LPS) (Sigma, USA) 0.1 µg/ml or
mycobacteria at 2 × 105 CFU/ml (at a ratio of 0.2 bacteria
per cell). Supernatants were collected at 0, 1, 6, 18, 48 and
120 h (5 days) post infection for chemokine measure-
ment, spun to collect cellular debris and stored at -70 C
until tested. BCG innoculum was tested for LPS contami-
nation using the E-Toxate Kit (Sigma, USA).
ELISAs
ELISA reagents for CCL2, CXCL8 and TNFα were from
R&D Systems (USA). Assays were carried out according to
the manufacturer's recommendation and as reported pre-
BMC Immunology 2005, 6:14 http://www.biomedcentral.com/1471-2172/6/14
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viously [43]. The lower limit of detection for CCL2 was
7.8 pg/ml, and 3.9 pg/ml for TNFα and CXCL8.
Statistical analysis
Data is expressed as Mean (SD) or Median as described in
figures. Statistical analysis was carried out using Mann-
Whitney U test for Pair-wise analysis of groups using the
SPSS package, USA and also ANOVA analysis.
List of abbreviations used
BCG, bacille-Calmette Guerin vaccine strain; LPS – lipo
polysaccharide; TNFα – tumor necrosis factor alpha; Pul-
TB – pulmonary tuberculosis; EPul-TB – extra-pulmonary
tuberculosis; EC – endemic controls; CCL2 – C-C chem-
okine ligand 2; CXCL8 – C-X-C chemokine ligand 8.
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